Hyperprogressive Disease During Atezolizumab Plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma from Japanese Real-World Practice Sae Yumita , Sadahisa Ogasawara , Miyuki Nakagawa , Susumu Maruta , Tomomi Okubo , Norio Itokawa , Yotaro Iino , Masamichi Obu , Yuki Haga , Atsuyoshi Seki , Tadayoshi Kogure , Takamasa Ishino , Keita Ogawa , Kisako Fujiwara , Terunao Iwanaga , Naoto Fujita , Takafumi Sakuma , Ryuta Kojima , Hiroaki Kanzaki , Keisuke Koroki , Masanori Inoue , Kazufumi Kobayashi , Soichiro Kiyono , Masato Nakamura , Naoya Kanogawa , Tomoko Saito , Takayuki Kondo , Ryo Nakagawa , Shingo Nakamoto , Ryosuke Muroyama , Tetsuhiro Chiba , Ei Itobayashi , Masanori Atsukawa , Yoshihiro Koma , Ryosaku Azemoto , Kenji Ito , Hideaki Mizumoto , Jun Kato , Naoya Kato BMC gastroenterology（2023）
关键词
Hyperprogressive disease, Atezolizumab and bevacizumab, Hepatocellular carcinoma, Immunotherapy
AI 理解论文
溯源树
样例
